American Clinical Laboratory Magazine Publishes Article on Aethlon Medical AIDS Treatment.

Business Editors and Health/Medical Writers

LA JOLLA, Calif.--(BW HealthWire)--Dec. 4, 2001

Aethlon Medical, Inc. (OTCBB:AEMD) announced today that an article authored by R.H. Tullis, J.A. Ambrus, Jr., and J.A. Joyce, entitled "HIV affinity hemodialysis as a treatment for AIDS," was published in the latest issue (Volume 20, No. 9, Page 22) of AMERICAN CLINICAL LABORATORY, a leading medical industry publication.

The article discusses AIDS as a worldwide problem of epidemic proportions; reviews the limitations of current drug treatments; and addresses the challenges of developing a usable vaccine for the highly mutative AIDS virus (HIV).

The article then describes a new treatment strategy utilizing the HIV-Hemopurifier(TM) from Aethlon Medical as a process to effectively remove HIV through affinity hemodialysis. The authors detail how the Aethlon Medical treatment augments the capacity of the immune system through the direct physical removal of infectious virus, thus inhibiting the re-infection of new cells. On average, Aethlon scientists were able to remove 55% of HIV from human blood in 3 hours, and 85 to 100% removal of HIV was documented in overnight treatment simulations.

The authors conclude that the HIV-Hemopurifier, which contains immobilized antibodies, is effective in removing HIV and toxic viral surface proteins from the blood of infected patients. The treatment is positioned to be an adjunctive therapy to currently available therapeutic regimes without the side effects of drugs as well as a stand-alone treatment for HIV patients who cannot tolerate drugs or who have become resistant to the available treatments.

Dr. Tullis is the Chief Scientific Officer and Joyce is the Chairman and CEO of Aethlon Medical Inc. Dr. Ambrus is Associate Professor of Medicine, Department of Immunology, at the University of Buffalo. Reprints of the article (1,459 words) can be ordered directly from International Scientific Communications Inc., 30 Controls Drive, P.O. Box 870, Shelton, Conn. 06484-0870, U.S.A. Phone [phone], or visit the ISC Web site at http://www.iscpubs.com.

About Aethlon Medical

Aethlon Medical is a development stage company that is expanding the applications of a novel, global therapeutic approach for treating HIV/AIDS and other epidemic diseases. The company's platform technology, known as the Hemopurifier(TM), is designed to rapidly reduce the presence of viruses and other intoxicants in the blood. The near term business strategy is to develop new therapies and standards of care for infectious diseases in two major revenue sectors, HIV/AIDS and Hepatitis-C (HCV). Aethlon Medical's lead product candidates, AEMD-45 and AEMD-61, are positioned to fill the urgent need for new HIV/AIDS treatments that are effective in reducing viral load, have fewer side effects, decrease treatment resistance, and protect immune functions. Pre-clinical trials of AEMD-45 consistently document a 55% removal of HIV from whole human blood in three hours and an 85-100% removal of HIV during the equivalent of one overnight treatment. For more information on Aethlon Medical Inc., visit the company's Web site at www.AethlonMedical.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical Inc. (the "company"), or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers of this press release may obtain additional information on the company in reports and other information filed in accordance with the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such reports and other information filed by the company can be inspected and copied at the public reference facilities maintained by the Commission at the Public Reference Room, 450 Fifth Street, N.W., Washington, D.C. 20549. Copies of such material can also be obtained at prescribed rates from the Public Reference Section of the Commission, Washington, D.C. 20549 or by calling the Commission at 800/SEC-0330. In addition, Registration Statements and other filings made with the Commission through its Electronic Data Gathering Analysis and Retrieval System ("EDGAR") and publicly available through the Commission's Web site located at http://www.sec.gov.